News

Stories

See all

CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access

View Story

Updates: Lilly's Global COVID-19 Response

View Story

Increasing Diversity in Clinical Trials

View Story

Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

View Story

Overcoming Barriers to Biomarker Testing in Cancer

View Story

Lilly’s Commitment to Quality Manufacturing

View Story


Press Releases

See all

Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine

October 28, 2020

Tags |  Product

INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19




Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19

October 28, 2020

Tags |  Product

- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials   - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.




Lilly Reports Third-Quarter Financial Results, Updates Guidance

October 27, 2020

Tags |  Financial

- Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.   - Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance,




New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

October 23, 2020

Tags |  Product

- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes   -